Local ablative therapy of oligoprogressive TKI-treated thyroid cancer

• Published in: Journal of endocrinological investigation Vol. 42; no. 8; pp. 871 - 879
• Main Authors: Porcelli, T., Sessa, F., Luongo, C., Salvatore, D.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01-08-2019; Springer Nature B.V
• Subjects: Catheter Ablation - methods; Combined Modality Therapy; Disease control; Endocrinology; Health risk assessment; Humans; Medicine; Medicine & Public Health; Metabolic Diseases; Metastases; Metastasis; Non-small cell lung carcinoma; Patients; Prognosis; Protein Kinase Inhibitors - therapeutic use; Protein-tyrosine kinase; Short Review; Thyroid cancer; Thyroid Neoplasms - pathology; Thyroid Neoplasms - therapy; Metastatic thyroid cancer; Lenvatinib; Thyroid cancer; Oligoprogression; Tyrosine kinase inhibitors; Local ablative therapy
• ISSN: 1720-8386; 0391-4097; 1720-8386
• DOI: 10.1007/s40618-019-1001-x

Metastatic cancer patients generally respond well to treatment with tyrosine kinase inhibitors (TKIs). However, TKI resistance occurs in almost all cases and often leads to a change in treatment. Recent guidelines, including thyroid cancer, raised the possibility of locally treating TKI-resistant oligoprogressive disease, i.e., one or a few progressing lesions in an otherwise treatment-responsive metastatic cancer, thereby obviating the need to change the ongoing TKI. To determine the benefits of this intervention, we reviewed studies on the use of LAT for TKI-treated oligoprogressive cancers. We found that in non-small cell lung cancer at least, LAT prolongs disease control and the duration of exposure to a TKI irrespective of the LAT used. Moreover, we reviewed the local ablative therapies (LATs) that are feasible for the local control of oligoprogressive thyroid cancer. Lastly, we report two illustrative cases of patients with oligoprogressive thyroid cancer treated with two different LATs while on therapy with TKIs. Both LATs extended the duration of disease control and the time of exposure to the ongoing TKI, thereby indicating that LAT is a favorable option for TKI-treated oligoprogressive thyroid cancer. Prospective randomized studies are needed to verify the benefit of LATs in terms of progression-free and overall survival in this increasingly frequent clinical setting.